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ABSTRACT 
The aim of this chapter is to provide a brief introduction into the basics of a  top-down multilevel  tumor 
dynamics modeling  method  primarily based on discrete entity consideration and manipulation. The 
method is clinically oriented, one of its major goals being to support patient individualized treatment 
optimization through experimentation in silico (=on the computer).  Therefore, modeling of the 
treatment response of clinical tumors lies at the epicenter of the approach.  Macroscopic data, including 
i.a. anatomic and metabolic tomographic images of the tumor, provide the framework for the integration 
of data and  mechanisms pertaining to lower and lower biocomplexity levels such as clinically approved 
cellular and molecular biomarkers. The method also provides a powerful framework for the 
investigation of multilevel (multiscale) tumor biology in the generic investigational context. The 
Oncosimulator, a multiscale physics and biomedical engineering concept and construct tightly 
associated with the method and currently undergoing clinical adaptation, optimization and validation, is 
also sketched. A brief outline of the approach  is provided in natural language. Two specific models of 
tumor  response to chemotherapeutic and  radiotherapeutic schemes are briefly outlined and indicative 
results are presented in order to exemplify the application potential of the method. The chapter 
concludes with a discussion of several important aspects of the method including i.a. numerical analysis 
aspects, technological issues, model extensions and validation within the framework of actual running 
clinico-genomic trials. Future perspectives and challenges are also addressed. 
 
1. INTRODUCTION 
 
The majority of cancer modeling techniques developed up to now adopt the straightforward bottom-up 
approach focusing on the better understanding and quantification of rather microscopic tumor dynamics 
mechanisms and the investigation of crucial biological entity interdependences including i.a. tumor 
response to treatment  in the generic investigational context. To this end several combinations of 
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mathematical concepts, entities and techniques have been developed and/or recruited and appropriately 
adapted. They include i.a. population dynamics models (Guiot et al 2006), cellular automata and hybrid 
techniques (Duechting and Vogelsaenger 1981; Duechting et al 1992; Ginsberg et al 1993; Kansal et al 
2000;  Stamatakos et al 2001a, 2001b; Zacharaki et al 2004), agent based techniques (Deisboeck et al 
2001), diffusion related continuous and finite mathematics treatments (Murray 2003; Swanson et al 
2002; Breward et al 2003; Cristini et al 2005; 1992; Frieboes et al 2006;  Enderling et al 2007; Ramis-
Conde et al 2008), etc. In addition, a number of large clinical tumor models focusing mainly on 
invasion and  tumor growth morphology rather than on tumor response to concrete therapeutic schemes 
as administered in the clinical setting have appeared. Finite difference and finite element based 
solutions of the diffusion and classical mechanics equations constitute the core working tools of the 
corresponding techniques (Murray 2003; Swanson et al 2002; Clatz et al 2005).  
 
Nevertheless, a number of concrete and pragmatic clinical questions of importance cannot be dealt with 
neither by the bottom-up approach nor by the morphologically oriented large tumor growth models in a 
direct and efficient way. Two examples of such questions are the following (Graf and Hoppe 2006): 
“Can the response of the local tumor and the metastases to a given treatment be predicted in size and 
shape over time?,  What is the best treatment schedule for a patient regarding drugs, surgery, irradiation 
and their combination, dosage, time schedule and duration?” A promising modeling method designed 
with the primary aim of answering such questions is the top-down method developed by  the In Silico 
Oncology Group  (ISOG)  ( In Silico Oncology Group , Stamatakos et al 2001c, 2002, 2006b, 2006c, 
2006d, 2006e, 2007a, 2007b, 2009a; Dionysiou et al 2004, 2006a, 2006b, 2006c; 2007; 2008; Antipas et 
al 2004, 2007; Stamatakos and Uzunoglu 2006b; Stamatakos and Dionysiou 2009) . Macroscopic data, 
including i.a. anatomic and metabolic tomographic images of the tumor, provide the framework for the 
integration of available and clinically trusted  biological information pertaining to lower and lower 
biocomplexity levels such as clinically approved histological and molecular markers. However, the 
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method does also provide a powerful framework for the investigation of multiscale tumor biology in the 
generic investigational context. 
 
From the mathematical point of view  the top-down simulation  method  presented is primarily a 
discrete mathematics method, although continuous mathematics (continuous functions, differerential 
equations) are used in order to tackle specific aspects of the models such as pharmacokinetics and cell 
survival probabilities based on pharmacodynamical and radiobiological models. Adoption of the 
discrete approach  as  the core mathematical strategy of the method   has been dictated by the obvious 
fact that from  the cancer treatment perspective it is the discrete i.e. the integer number of the usually 
few biological cells surviving treatment and their discrete mitotic potential categorization (stem cells, 
progenitor cells of various mitotic potential levels and differentiated cells) that really matter. These 
discrete entities and quantities in conjunction with their complex interdependences may give rise to 
tumor relapse or to ensure tumor control over a given time interval following completion of the 
treatment course. Cell cycle phases have a clearly discrete character too. Moreover, the properties of the 
different cell phases may vary immensely from the clinical significance perspective. A classical 
example is the lack of effect of cell cycle specific drugs on living tumor cells residing in the resting G0 
phase.  
 
It is noted that complex interdependencies of microscopic factors in the surroundings  of the cells such 
as oxygenation, nutrient supply and molecular signals emitted by other cells play a critical role in the 
mitotic fate of tumor cells. Their effect is taken into account in  the method through the local mean 
values of the corresponding model parameters. To this end imaging, histological and molecular data is 
exploited as will be described further down. 
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Due to the numerical character of the method a careful and realistically thorough numerical analysis 
concerning consistency, convergence and sensitivity/stability issues is absolutely necessary before any 
application is envisaged. A discussion of this critical issue is included in Section 5. 
 
Tumor neovascularisation is taken into account in an indirect yet pragmatic way by exploiting grey 
level and/or color information contained within slices of tomographic imaging modalities sensitive to 
blood perfusion and/or the metabolic status of the tumor.  (Stamatakos et al 2001a,2002, 2006c; 
Dionysiou et al 2004, 2007; Marias et al 2007). The reason for adopting the above mentioned strategy 
rather than developing or integrating detailed tumor angiogenesis models is that no microscopic 
information regarding the exact mesh of the neovascularization capillaries throughout the tumor can be 
currently extracted from clinically utilized imaging modalities. Nevertheless, the microscopic functional 
capillary density distribution over the tumor can be grossly estimated based on various imaging 
modalities such as T1 gadolinium enhanced MRI in the case of glioblastoma multiforme (GBM) and 
arterial spin labelling (ASL) MRI. 
 
Precursors of  the method can be traced in the well established and clinically applicable disciplines of 
pharmacology and radiobiology.  Integration of molecular biology in  the top-down method may be 
viewed as the introduction of a perturbator or adaptor of the cellular and higher biocomplexity level 
parameters. In such a way in vivo measurable clinical manifestation of tumor dynamics is placed the 
foreground. This is one of the reasons why the method is gaining wider and wider acceptance within the 
clinical and the industrial environment including the emergent domain of in silico oncology 
(Stamatakos et al 2002, 2006a, 2007b, 2008, 2009a; Graf and Hoppe 2006; Graf et al 2007, 2009). Both 
the large scale European Commission (EC) and Japan funded ACGT research and development (R&D) 
project (ACGT) and the EC funded ContraCancrum R&D project (ContraCancrum) have adopted the 
top-down method  as their core cancer simulation method. It is worth noting that in both projects the 
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role of clinicians is prominent. A biomedical engineering concept and construct tightly associated with 
the method, the Oncosimulator, which is currently under clinical adaptation, optimization and 
validation is also sketched. 
 
In order to convey the core philosophy of the method to the reader in a concise way a symbolic 
mathematical formulation of the top-down  method  in terms of a hypermatrix and discrete operators is 
introduced. Two specific models of tumor response to chemotherapeutic and radiotherapeutic 
schemes/schedules  are briefly outlined so as to exemplify the method’s application potential. The 
chapter concludes with a discussion of several critical aspects including numerical analysis, massive 
parallel code execution, associated technologies, extensions and validation within the framework of 
clinico-genomic trials and future challenges and perspectives. 
 
A rather encouraging fact as far as industrial and eventually clinical translation of the method is 
concerned is that both the top-down method outlined and the Oncosimulator have been selected and 
endorsed by a worldwide leading medical technology company and now constitute modules of their 
research and development line (ContraCancrum). One of the envisaged final products of this endeavor 
is a radiotherapy treatment planning system based on both physical and multiscale biological 
optimization of the spatiotemporal dose administration scheme. A clinical trial based validation process 
for the system is currently at the final stage of its detailed formulation.  
 
2. THE ONCOSIMULATOR 
 
The Oncosimulator  can be defined as a concept of multilevel integrative cancer biology, a complex 
algorithmic construct, a biomedical engineering system and (eventually in the future) a clinical tool 
which primarily aims at supporting the clinician in the process of optimizing cancer treatment in the 
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patient individualized context through conducting experiments in silico  i.e. on the computer. 
Additionally it is a platform for simulating,  investigating,  better understanding and exploring the 
natural phenomenon of cancer, supporting the design and interpretation of clinicogenomic trials and 
finally training doctors, researchers and interested patients alike (Stamatakos et Uzunoglu 2006b; 
Stamatakos et al 2007a; Graf et al 2009).    
    
A synoptic outline of the clinical utilization of a specific version of the Oncosimulator, as envisaged to 
take place following an eventually successful completion of its clinical adaptation, optimization and 
validation process, is provided in the form of the following seven steps (Figure 1).  
 
1
st
  step: Obtain patient’s individual multiscale and inhomogeneous data. Data sets to be collected for 
each patient include: clinical data (age, sex, weight etc.), eventual previous anti-tumor treatment history, 
imaging data (e.g. MRI, CT, PET etc images), histopathological data (e.g. detailed identification of the 
tumor type, grade and stage, histopathology slide images whenever biopsy is allowed and feasible etc.), 
molecular data (DNA array data, selected molecular marker values or statuses, serum markers etc.). It is 
noted that the last two data categories are extracted from biopsy material and/or body fluids.  
 
2
nd
 step: Preprocess patient’s data. The data collected are preprocessed in order to take an adequate 
form allowing its introduction into the “Tumor and Normal Tissue Response Simulation” module of the 
Oncosimulator. For example the imaging data are segmented, interpolated, eventually fused and 
subsequently the anatomic entity/-ies of interest is/are three dimensionally reconstructed. This 
reconstruction will provide the framework for the integration of the rest of data and the execution of the 
simulation. In parallel the molecular data is processed via molecular interaction networks so as to 
perturb and individualize the average pharmacodynamic or radiobiological cell survival parameters.  
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3
rd
  step: Describe one or more candidate therapeutic scheme(s) and/or schedule(s). The clinician 
describes a number of candidate therapeutic schemes and/or schedules and/or no treatment, obviously 
leading to free tumor growth, to be simulated in silico i.e. on the computer.  
 
4
th
  step: Run the simulation. The computer code of tumor growth and treatment response is massively 
executed on distributed grid or cluster computing resources so that several candidate treatment schemes 
and/or schedules are simulated for numerous combinations of possible tumor parameter values in 
parallel (see Section 5 for detailed justification). Predictions concerning the toxicological compatibility 
of each candidate treatment scheme are also produced.  
 
5
th
  step: Visualize the predictions. The expected reaction of the tumor as well as toxicologically 
relevant side effect estimates for all scenarios simulated are visualized using several techniques ranging 
from simple graph plotting to four dimensional virtual reality rendering.  
 
6
th
  step: Evaluate the predictions and decide on the optimal scheme or schedule to be administered to 
the patient. The Oncosimulator’s predictions are carefully evaluated by the clinician by making use of 
their logic, medical education and even qualitative experience. If no serious discrepancies are detected, 
the predictions support the clinician in taking their final and expectedly optimal decision regarding the 
actual treatment to be administered to the patient.  
 
7
th
  step: Apply the theoretically optimal therapeutic scheme or schedule and further optimize the 
Oncosimulator. The expectedly optimal therapeutic scheme or schedule is administered to the patient. 
Subsequently, the predictions regarding the finally adopted and applied scheme or schedule are 
compared with the actual tumor course and a negative feedback signal is generated and used in order to 
optimize the Oncosimulator.  
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PLEASE PLACE FIGURE 1 (INCLUDING FIG. CAPTION) HERE 
 
3. A BRIEF OUTLINE OF THE BASICS OF THE ISOG TOP-DOWN METHOD  
 
3.1 The Multilevel Matrix of the Anatomical Region of Interest  
The anatomical region of interest, primarily including the tumor and possibly adjacent normal tissues 
and edema, in conjunction with its biological, physical and chemical dynamics is represented by a 
multilevel matrix i.e. a  
Matrix of (Matrices of (Matrices…of (Scalars or Vectors or Matrices )…)). 
The multilevel  matrix is created by a cubic discretization mesh which is virtually superimposed upon 
the anatomical region of interest. Biological cells residing within each geometrical cell of the mesh are 
conceptually clustered into mathematical equivalence classes. Equivalence classes primarily correspond 
to the various phases within or out of the cell cycle that a biological cell of the tumor can be found. 
Since a tumor cell at any given instant also belongs to a mitotic potential category (stem, progenitor, 
terminally_differentiated) the latter acts as a further partitioner of the biological cells into equivalence 
classes. One of the reasons, though not the single most important, for clustering biological cells into 
equivalence classes within each geometrical cell of the discretization mesh is computing resource 
limitations. Complex computational treatment of each single cell of a large clinical tumor undergoing 
therapeutic treatment as a separate entity is still not achievable within acceptable resource and time 
limits.  
 
Discrete time is used. An important discretization aspect of the method is the mean time spent in the 
phase of an equivalence class by the biological cells belonging to the equivalence class (Stamatakos et 
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al 2001c, 2002, 2006c, 2006e; Dionysiou et al 2004, 2006; Stamatakos and Dionysiou 2009b). In order 
to allow for spatiotemporal perturbations of critical parameter values throughout the tumor and also 
avoid artificial cell synchronizations due to quantization, use of pseudo-random numbers is extensively 
made (Monte Carlo technique).  
 
3.2. Practical Considerations Regarding the Construction of the Discretization Mesh 
Collection of the appropriate mono-modality or far better multi-modality tomographic data of the 
patient such as slices of T1 weighted contrast enhanced MRI, T2 weighted MRI, CT, PET or other 
modalities, image segmentation, slice  interpolation, three dimensional reconstruction of the anatomical 
entities of interest centered at the tumor, and eventually fusion of more than one modality images 
constitute the initial steps for the creation of the discretization mesh covering and discretizing the 
anatomical region of interest. Processed microscopic data (histological, molecular) are then utilized in 
order to enhance the patient individualization of the hypermatrix. 
 
3.3 The basics of the top-down method 
The multilevel matrix corresponding to the anatomical region of interest describes explicitly or 
implicitly the biological, physical and chemical dynamics of the region. The following parameters are 
used in order to identify a cluster of biological cells belonging to a given equivalence class within a 
geometrical cell of the mesh at a given time point: 
I.   the spatial coordinates of  the discrete points of the discretization mesh with spatial indices i, j, k 
respectively. Each discrete spatial point lies at the center of a geometrical cell of the discretization  
mesh. 
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II.   the temporal coordinate of the discrete time point with temporal index l 
III.  the  mitotic potential category (i.e. stem or progenitor or terminally differentiated)  of the biological 
cells with mitotic potential category index m 
IV.  the cell phase (within or out of the cell cycle) of the biological cells with cell phase index n. The 
following phases are considered:                         where G1 denotes the G1 cell cycle phase; S 
denotes the DNA synthesis phase; G2 denotes the G2 cell cycle phase; M denotes mitosis; G0 denotes 
the quiescent (dormant) G0 phase; A denotes the apoptotic phase; N denotes the necrotic phase and D 
denotes the remnants of dead cells. 
 
For the biological cells belonging to a given mitotic potential category AND  residing in a given cell 
phase AND  being accommodated within the geometrical cell whose center lies at a given spatial point 
AND  being considered at a given  time point - in other words for the biological cells clustered in the 
same equivalence classs denoted by the index combination  ijklmn - the following state parameters are 
provided  
i.   local oxygen and nutrient provision level.  The following possible binary values of this parameter  
were initially considered: “oxygen and nutrient provision level sufficient for tumor cell proliferation” 
and “oxygen and nutrient provision level insufficient for tumor cell proliferation”. Obviously the binary 
character of the oxygen and nutrient provision level is to be considered only a first simplifying 
approximation. More elaborate descriptions have been proposed and applied (Stamatakos et al 2002, 
2006c, 2006d; Dionysiou et al 2004, 2006a; Antipas et al 2004). 
ii.  number of biological cells 
iii. average time spent by the biological cells in the given phase 
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iv. number of biological cells hit by treatment 
v. number of biological cells not hit by treatment   
The initial constitution of the tumor i.e. its biological, physical and chemical state has to be estimated 
based on the available medical data through the application of pertinent algorithms ( Kolokotroni et al 
2008; Georgiadi et al 2008) . This state corresponds to the instant just before the start of the treatment 
course to be simulated.  
 
The entire simulation can be viewed as the periodic and sequential application of a number of sets of 
algorithms on the multilevel matrix of the anatomical region of interest. Thus a stepwise multilevel 
matrix updating is achieved.  Each algorithm set application period is equal to the time separating two 
consecutive complete scans of the discretization  mesh. A complete scan includes mesh scans 
performed by all algorithm sets for any given time point. The algorithm set application period is usually 
taken 1 h since this is approximately the duration of mitosis, the shortest of the cell cycle phases. It 
should be noted that although the parameter values exported by the simulation execution at any desired 
instant for visualization and analysis purposes have a discrete character, certain parameters are handled 
by the computer internally and temporarily as real numbers (even with enhanced precision) in order to 
minimize quantization error propagation, in particular when dealing with small numbers of discrete 
entities in the stochastic context. By no means, however, does this technicality affect the fundamentally 
discrete character of the top-down method described. 
 
The application  of  the algorithm sets on the multilevel matrix of the anatomic region of interest takes 
place in the following order: 
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A.  Time updating i.e. increasing time by a time unit (e.g. 1h) 
B.    Estimation of  the local oxygen and nutrient provision level 
C.   Estimation of the effect of treatment (therapy) referring mainly to cell hitting by treatment, cell 
killing and cell survival. 
D.    Application of cell cycling, possibly perturbed by treatment. Transition between mitotic potential 
cell categories such as transition of the offspring of a terminally divided progenitor cell into the 
terminally differentiated cell category is also tackled by this algorithm set. 
E.   Differential expansion or shrinkage or more generally geometry and mechanics handling. 
F.    Updating the local oxygen and nutrient provision level following application of the rest of 
algorithm sets at each time step   
It is noted  that the outcome of appropriate processing of the molecular and/or histopathological data via 
e.g. molecular networks and signaling pathways is used as a perturbator of the cell survival probabilities 
included in algorithm set  “C”  so as to considerably enhance patient individualization of the simulation. 
A realistic estimate of the extent of such  perturbations for a given tumor type subclass in the 
framework of a clinico-genomic trial is achieved in a stepwise way. Initial rough modifications of the 
cell survival probabilities based on the baseline-pretreatment data,  pertinent literature information and 
logic are subsequently corrected through utilization of the corresponding post treatment data via a 
process of parameter fitting.  
Obviously the above mentioned concepts and  briefly outlined steps cannot convey all the details 
needed for the simulation to run. Their role is rather to identify and decompose the major conceptual 
mathematical and computational steps than to list all modeling details. The interested reader is referred 
to the website of the In Silico Oncology Group where they may find lists of pertinent publications 
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providing detailed descriptions of several top-down multilevel cancer models including i.a. 
assumptions, mathematical treatment, numerical aspects such as convergence and quantization error 
minimization, sensitivity analysis, validation, applications and suggested extensions.  
 
It is worth noting that discrete simulation under certain constraints can efficiently replace analytical 
solutions to a wide range of mathematical problems which, although being formulated in terms of 
continuous mathematics - usually including symbolically formulated differential equations - refer in fact 
to discrete physical quantities such as biological cells and cell state transition rates. Moreover, in many 
cases the continuous symbolic formulation of mathematical operators, such as the well known 
differential operator, when acting on discrete physical quantities can be readily replaced by a 
conceptually more straightforward algorithmic formulation. Several techniques leading to the 
minimization of error propagation for those cases where small numbers of discrete entities are dealt 
with by stochastic processes are available. The above generic policy has been extensively adopted in 
top-down multiscale   models. For extensions of the method  currently under implementation see 
Section 5.  
 
4. EXAMPLES OF APPLICATIONS OF THE  ISOG TOP-DOWN METHOD - RESULTS 
 
In this section two indicative models denoted by Model A and Model B are briefly outlined so as to 
exemplify the application potential of the method in the clinical context. 
 
4.1 Model A: Tumor Response to Chemotherapeutic Schedules  
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Model A is a four dimensional, patient specific top-down simulation model of solid tumor response to 
chemotherapeutic treatment in vivo. The special case of imageable glioblastoma multiforme (GBM) 
treated by temozolomide (TMZ) has been addressed as a simulation paradigm.  However, a 
considerable number of the involved algorithms are quite generic. The model is based on the patient’s 
imaging, histopathologic and genetic data. For a given drug administration schedule lying within 
acceptable toxicity boundaries, the concentration of the prodrug and its metabolites within the tumor is 
calculated as a function of time based on the drug pharamacokinetics. A discretization mesh is 
superimposed upon the anatomical region of interest and within each geometrical cell of the mesh the 
basic biological, physical and chemical “laws” such as the rules concerning oxygen and nutrient 
provision, cell cycling (Salmon and Sartorelli 2001), mechanical deformation etc. are applied at each 
discrete time point. The biological cell fates are predicted based on the drug pharmacodynamics 
(Newlands et al 1992;  Bobola et al 1996;  Perry 2001; Katzung 2001; FDA; Chinot et al 2001; Stupp et 
al 2001). The outcome of the simulation is a prediction of the spatiotemporal activity of the entire tumor 
and is i.a. virtual reality visualized. A good qualitative agreement of the model’s predictions with 
clinical experience (Stamatakos et al 2006d, 2006e) supports the applicability of the approach. Model A 
has provided a basic platform for performing patient individualized in silico experiments as a means of 
chemotherapeutic treatment optimization in the theoretical context. A few indicative aspects of the 
model are outlined  below. Since the complexity of the analysis is high the interested reader is referred 
to (Stamatakos et al 2006d, 2006e) for a detailed description of the model. The work has also provided 
the basis for the development of the ACGT (ACGT) and ContraCancrum (ContraCancrum) 
chemotherapy treatment response models. 
PLEASE PLACE FIGURE 2 (INCLUDING FIGURE CAPTION) HERE 
Figure 2 depicts the simplified cytokinetic model of a tumor cell that has been proposed and adopted in 
Model A. The cytotoxicity produced by TMZ is primarily modeled by a delay in the S phase 
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compartment (TDS) which is denoted by “Delay due to the effect of chemotherapy” in the diagram of 
Figure 2 and by subsequent apoptosis. Further details are provided in the caption of Figure 2. 
PLEASE PLACE FIGURE 3 (INCLUDING FIGURE CAPTION) HERE 
Figure 3 provides a three dimensional visualization of the simulated response of a clinical GBM tumor 
to one cycle of the TMZ chemotherapeutic scheme:  150 mg/m
2
 orally once daily for 5 consecutive days 
per 28-day treatment cycle (Stamatakos et al 200d).  Panel (a) shows the external surface of the tumor 
before the beginning of chemotherapy. Panel (b) shows the internal structure of the tumor before the 
beginning of chemotherapy. Panel (c) shows the predicted external surface of the tumor 20 days after 
the beginning of chemotherapy. Panel (d) shows the predicted internal structure of the tumor 20 days 
after the beginning of chemotherapy. The pseudo-coloring criterion proposed and utilized is described 
in the caption of Figure 3. 
 
4.2  Model B: Tumor Response to Radiotherapeutic Schedules  
 
Model B is a spatiotemporal simulation model of in vivo tumor growth and response to radiotherapy    
exemplified by the special case of imageable GBM treated by the treatment modality under 
consideration. The main constitutive processes of the model can be summarized as follows. A 
discretizing cubic mesh is superimposed upon a three dimensional virtual reconstruction of the tumor 
including its necrotic region and the surrounding anatomical features based on imaging data. In a way 
analogous to Model A, within each geometrical cell of the mesh a number of biological cell equivalence 
classes are defined based i.a. on the biological cell distribution over the various phases within or out of 
the cell cycle for the various mitotic potential categories. Sufficient registers are used in order to store 
the current state of each equivalence class such as the average time spent by clustered biological cells in 
phase G1 etc. The mesh is scanned every one hour. The basic biological, physical and chemical “laws”  
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or more precisely rules including the metabolic activity dynamics, cell cycling, mechanical and 
geometrical aspects,  cell survival probability following irradiation with dose D (Perez and Brady 1998; 
Steel 2002) are applied on each geometrical cell at each complete scan. A spatial and functional 
restructuring of the tumor takes place during each discrete time point since new biological cells are 
eventually produced, leading to differential tumor growth, or existing cells eventually die and 
subsequently disappear through specific molecular and cellular event cascades, thus leading to 
differential tumor shrinkage. Simulation predictions can be two or three dimensionally visualized at any 
simulated instant of interest. In the particular model special attention has been paid to the influence of 
oxygenation on radiosensitivity in conjunction with the introduction of a refined imaging based 
description of the neovasculature density distribution. In order to validate the model two identical - 
except for the p53 gene status - virtual GMB tumors of large size, complex shape and complex internal 
necrotic region geometry were considered.  The first one possessed a wild type p53 gene whereas the 
second one was characterized by a mutated p53 (Stamatakos et al 2006c; Dionysiou et al 2004).  The 
values of the α and β parameters of the standard linear quadratic radiobiological model for cell survival  
(Steel 2002, Perez and Brady 1998) have been determined experimentally for the two cell lines 
considered (Haas-Kogan et al 1995).  Simulation predictions agree at least semi-quantitatively with 
clinical experience and in particular with the outcome of the Radiation Therapy Oncology Group RTOG 
Study 83 02 (Werner-Wasik et al 1996). The model allows for a quantitative study of the inter-
relationship between the competing influences in a complex, dynamic tumor environment. Therefore, 
the model is already useful as an educational tool with which to theoretically study, understand and 
demonstrate the role of various parameters on tumor growth and response to irradiation. A long term 
quantitative clinical adaptation and validation of a considerably  extended version of the model is in 
progress within the framework of the ContraCancrum project (ContraCancrum). The long term goal is 
obviously integration into the clinical treatment planning procedure. 
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Figure 4 shows simulation predictions corresponding to several branches of the RTOG Study 83 02. 
Panel (a) provides  the total number of proliferating and dormant tumor cells as a function of time for 
the hyperfractionated (1.2 Gy twice daily, 5 days per week to the dose of 72 Gy, “HF-72”) and 
accelerated hyperfractionated (1.6 Gy twice daily, 5 days per week to the dose of 48 Gy, “AHF-48”) 
radiotherapy schedules. All schemes start on the first day of the radiotherapy course.  HF-72 is 
completed on day 40 after initiation of treatment whereas AHF-48 is completed on day 19.  Figure 4(b) 
shows the total number of proliferating and dormant tumor cells as a function of time for the 
hyperfractionated (1.2 Gy twice daily, 5 days per week to the dose of 64.8 Gy, “HF-64.8”) and 
accelerated hyperfractionated (1.6 Gy twice daily, 5 days per week to the dose of 48 Gy, “AHF-48”) 
radiotherapy schedules. Both irradiation schedules start on the first day of the first week of treatment.  
Both irradiation schedules start on the first day of the first week of treatment. HF-64.8 is completed on 
day 37 after initiation of treatment whereas AHF-48 is completed on day 19. According to the graphs, 
before completion of the AHF course cell kill due to AHF irradiation is more pronounced than cell kill 
induced by the HF scheme. This can be explained by the fact that a higher total dose has been 
administered to the tumor by the AHF scheme whereas for the period under consideration both schemes 
are characterized by the same time intervals between consecutive sessions. In case that not all living 
cells have been killed by AHF irradiation, tumor repopulation is considerable so that by the time the HF 
scheme is completed living tumor cells and their progeny which have escaped AHF irradiation 
outnumber tumor cells which have escaped HF irradiation. Improved tumor control following HF 
irradiation in comparison with the AHF scheme is in agreement with the conclusions of the clinical trial 
RTOG-83-02. 
 
 
PLEASE PLACE FIGURE 4 (INCLUDING FIGURE CAPTIONS) HERE 
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5. DISCUSSION  
 
Since the top-down  multilevel  method presented is a numerical method, a thorough convergence and 
sensitivity/stability analysis that includes the study of multiple parameter interdependences is necessary  
before any application is envisaged. Numerical analysis should satisfactorily cover at least those regions 
of the abstract parameter space that correspond to the envisaged applications. It is noted that of 
particular importance is the creation of the baseline tumor constitution by exploiting the relevant 
multilevel  data available. Convergence of the tumor initialization has to be ensured. All of the above 
issues have been successfully addressed for specific tumor treatment cases such as breast cancer treated 
with epirubicin and nephroblastoma treated with vincristine and dactinomycin.  The numerical behavior 
of the corresponding models has been checked through massive numerical experimentation. Concrete 
applicability intervals, restrictions and limitations have been identified (Internal ACGT project reports 
and deliverables; Kolokotroni et al 2008; Georgiadi 2008). Since the entire parameter space of the top-
down models is rather large, numerical studies covering regions that correspond to further applications 
are in progress. Special attention is paid to the inherent relative biological instability of the cancer 
system itself when the model’s stability is investigated. 
 
It is well known that the values of critical parameters determining treatment outcome can vary 
considerably around what is assumed to be their population based average values.  Even after 
incorporation of patient specific multiscale data into the simulation model no accurate evaluation of 
several critical model parameters is expected to be achieved. Moreover, as already mentioned, a tumor 
may behave as a relatively unstable system. Therefore, in order to compare candidate treatment schemes 
and/or schedules in silico, several possible combinations of parameter values lying around their 
apparently most probable estimates have to be constructed so as to cover the abstract parameter space as 
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best as possible. Code executions have to be performed for all these selected parameter combinations. If 
for example the clinical question addressed is “Which out of the two candidate treatment schedules 
dented by I and II is the most promising for a given patient?”, simulations have to run for both 
schedules I and II and for all parameter value combinations selected in the way briefly delineated 
above. If based on the simulation predictions schedule I outperforms schedule II for a sufficiently large 
percentage of the total parameter combinations considered, say 90%, then there is ground to suggest 
adoption of schedule I.  Candidate scheme/schedule selection criteria are currently under formulation in 
tight collaboration with specialist clinicians within the framework of the ACGT (ACGT) and 
ContraCancrum (ContraCancrum) R&D projects. Obviously the above sketched treatment optimization 
strategy dictates the need for a large number of parallel code executions on either cluster of grid 
platforms. This necessity has been addressed by specific actions of the previosly mentioned projects. 
 
Critical constraints imposed by toxicological limits of the treatment affected normal tissues should also 
be taken into account in order to judge whether or not a candidate scheme could be toxicologically 
acceptable. This issue may be addressed by exploiting the outcome of eventually relevant clinical trials 
and in particular of their phase I results. Ideally, direct multiscale spatiotemporal simulation of the 
effects of a given candidate scheme on specific normal tissues would provide quantitatively refined 
predictions. Nevertheless, due to the extremely high complexity of the homeostatic mechanisms 
governing normal tissue dynamics, the large number of normal tissue functional aspects and the 
potential induction of serious late effects by treatment such as radiotherapy, clinical translation of the 
second scenario seems to be a long term enterprise (Antipas et al 2007). 
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Since many solid tumors are microscopically inhomogeneous in space, the applications presented so far 
essentially make use of the mean values of certain biological parameters over each imaging based  
segmented sub-region of the tumor ( Stamatakos et al 2002, 2006b, 2006c, 2006d, 2006e, 2007b, 
Dionysiou et al 2004, 2006a, 2006c; 2007; 2008; Antipas et al 2004, 2007).  Small perturbations around 
these values are nevertheless implemented across each region through Monte Carlo simulation by the 
top-down method presented. In the paradigmal case of MRI T1 gadolinium enhanced imaging modality, 
strong grey level fluctuations over a tomographic slice can lead to an approximate delineation of the 
internal necrotic and the well  neovascularized region of the tumor. Despite the fact that different values 
of certain parameters may be assigned to these two regions, sub-imaging scale inhomogeneties may still 
create spatial fluctuations of certain parameter values. In order to theoretically investigate the role of 
such biological inhomogeneities, pertaining for example to the genotypic and/or phenotypic tumor 
constitution, as well as the role of biochemical inhomogeneities of the extra tumoral environment such 
as acidity, necrosis exudate concentration etc the top-down   basic platform can be still used provided 
that specific adaptations have taken place. Furthermore, tumor cell - tumor cell, tumor cell - host cell 
and tumor cell - local environment interactions in the microscopic setting can in principle be studied. In 
order to implement the above scenarios, the density of the discretization mesh should considerably 
increase, deeper level partitioning into more equivalence (sub-)classes has to be introduced into the 
multilevel matrix of the anatomical region of interest and the algorithm sets should be extended 
accordingly. However, such an approach dictates a sharp increase in computing memory and time 
demands and therefore tumor size must be kept small if restrictions in these resources apply, as is 
usually the case. 
 
Following appropriate adaptation of specific modeling modules or equivalently algorithm sets such as 
the “C” set referring to cell killing etc.  the top-down method outlined  is in principle able to simulate 
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tumors of any shape, size, geometry, macroscopic distribution of the metabolic or neovascularisation 
field, differentiation grade, spatial inhomogeneities, molecular profile and treatment scheme/schedule 
such as radiotherapeutic, chemotherapeutic, combined, new treatment modality etc. However, great care 
should be taken so that the model parameter values are estimated as best as possible based on real 
multilevel  data.  If such data is not available use of at least population based average parameter value 
estimates or qualitative experience based plausible values may be utilized only for generic exploratory 
reasons.  
 
Hybridization of  the top-down method presented with continuous and finite mathematics approaches 
such as diffusion based tumor growth modeling and detailed biomechanics is currently under 
implementation (ContraCancrum). The aim of the task is to integrate into a top-down GBM model the 
microscopic tumor invasion process. The detailed biomechanics of the system calculated via a finite 
element module is also being integrated. Such a hybrid model is expected to be able to reproduce in 
relative detail both physical and biological aspects of tumor dynamics within the generic 
investigational framework. It should be noted that the non imageable diffusive component of GBM 
does play an important role in the development of the disease and therefore merits an in depth 
theoretical investigation. However, since the non imageable boundaries of GBM cannot be defined and 
monitored in a sufficiently objective way i.e. based on observational data such as clinically obtainable 
tomograhic images,  direct handling  of the non imageable component by treatment  planning systems in 
the patient individualized treatment context seems not to be a fully mature  scenario as yet. 
Furthermore, by focusing on the imageable component within the treatment optimization context, one 
may argue that if for the imageable component a candidate treatment scheme denoted by scheme I 
outperforms another candidate scheme denoted by scheme II in silico, the same would be true for the 
non imageable component of the tumor as well. From the treatment perspective again  the main 
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advantage of focusing  on the imageable component, although this may represent even less than half of 
the total number of all viable tumor cells, is that this very component is amenable to relatively objective 
measurement in vivo and not only post mortem. Therefore, glioma dynamics models based on the 
imageable component are amenable to validation, at least in part, in vivo. Besides, incorporation of the 
immune system response to tumor (D’Onofrio 2005) and simulation of the effects of antiangiogenetic 
drugs on the tumor are two further scenarios, currently under investigation in the ACGT Oncosimulator 
extension context (ACGT). 
 
Referring to the molecular level from the generic investigational standpoint, a large number of 
mechanisms, such as pathways leading to apoptosis or survival, that can be informed by available  
molecular data can be readily integrated into top-down models by applying  the summarize and jump 
strategy of bio-data and bio-knowledge integration across bio-complexity scales (Stamatakos et al 
2009a). This is in fact one of the actions currently taking place within the framework of the 
ContraCancrum  project (ContraCancrum). However, if the same biocomplexity level is viewed from 
the clinical perspective, care has to be taken so that only those characteristics and /or mechanisms 
whose predictive potential has been proved and established  in the  clinical setting - normally through 
clinical trials – may be incorporated into the models.  
 
Regarding the envisaged clinical translation of  top-down based models and systems, including the 
Oncosimulator, a sine qua non prerequisite is a systematic, formal and strict clinical validation. 
Designing the models so as to mimick actual clinical or far better clinico-genomic trials seems to be the 
optimal way to achieve this goal (Stamatakos et al. 2006c, 2007a; Graf and Hoppe 2006; Graf 2007, 
2008, 2009). Therefore, involvement of clinicians in the model and system design and validation 
process should start at the very beginning of the endeavor (Graf 2007, 2008, 2009). Real clinicogenomic 
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trials can provide invaluable multiscale data (imaging, histological, molecular, clinical, treatment) 
before, during and after a treatment course so as to best adapt and optimize the models and subsequently 
validate them. This is one of the core tasks of both the ACGT (ACGT) and the ContraCancrum R&D 
(ContraCancrum) projects. Nephroblastoma and breast cancer are the tumor types addressed by ACGT 
whereas gliomas and lung cancer are the ones addressed by ContraCancrum. 
 
A further important challenge is to develop reliable, efficient, highly versatile and user friendly 
technological platforms which, following clinical adaptation, optimization and validation of  the models 
would facilitate translation of oncosimulators into the clinical practice so as to efficiently support, 
enhance and accelerate patient individualized treatment optimization. Advanced image processing, 
visualization and parallel code execution modules are but a few of the components necessary to achieve 
this goal.  Both the ACGT and ContraCancrum R&D projects constitute exemplary initiatives towards 
this direction. 
 
In summary both the top-down multilevel cancer simulation method briefly outlined above and the 
Oncosimulator have been designed so as to be readily optimizable, extensible and adaptable to 
changing clinical, biological, and research envirionments. Thus both entities, being primarily multiscale 
physics and biomedical engineering geared, have a  pragmatic and evolutionary character.  
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Figure 1: The Oncosimulator: a gross workflow diagram  
Figure 2: Simplified cytokinetic model of a tumor cell proposed and adopted in model A. Symbols: G1: 
G1 phase; S: DNA synthesis phase; G2: G2 phase; G0: G0 phase; N: necrosis; A: apoptosis. The 
cytotoxicity produced by TMZ is primarily modeled by a delay in the S phase compartment (TDS) 
(“Delay  due to the effect of chemotherapy” in the diagram) and subsequent apoptosis. The delay box 
simply represents the time corresponding to at most two cell divisions being required before the 
emergence of temozolomide cytotoxicity. It is not a time interval additional to the times represented by 
the cell cycle phase boxes. (From Stamatakos G. S., Antipas V. P. and N.K.Uzunoglu. 2006. A 
spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in 
vivo: the paradigm of glioblastoma multiforme treated by temozolomide. IEEE Trans Biomed Eng 
53(8): 1467- 1477. Reprinted with permission from the Institute of Electrical and Electronics Engineers 
(IEEE), © 2006 IEEE) 
 
Figure 3: A three dimensional visualization of the simulated response of a clinical GBM tumor to one 
cycle of the TMZ chemotherapeutic scheme:  150 mg/m
2
 orally once daily for 5 consecutive days per 
28-day treatment cycle. (a) external surface of the tumor before the beginning of chemotherapy, (b) 
internal structure of the tumor before the beginning of chemotherapy, (c) predicted external surface of 
the tumor 20 days after the beginning of chemotherapy (d) predicted internal structure of the tumor 20 
days after the beginning of chemotherapy. The following pseudocolor code has been applied:  red: 
proliferating cell layer; green: dormant cell layer (G0); blue: dead cell layer. The “99.8%” pseudo-
coloring criterion has been devised and applied as follows. “For a geometrical cell of the discretizing 
mesh, if the percentage of dead cells within it is lower than 99.8% then {if percentage of proliferating 
cells > percentage of G0 cells, then paint the geometrical cell red (proliferating cell layer), else paint the 
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geometrical cell green (G0 cell layer)} else paint the geometrical cell blue (dead cell layer).” (From 
Stamatakos G. S., Antipas V. P. and N.K.Uzunoglu. 2006. A spatiotemporal, patient individualized 
simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma 
multiforme treated by temozolomide. IEEE Trans Biomed Eng 53(8): 1467- 1477. Reprinted with 
permission from the Institute of Electrical and Electronics Engineers (IEEE), © 2006 IEEE) 
 
 
 
Figure 4: Simulation predictions corresponding to several branches of the RTOG Study 83 02. (a) Total 
number of proliferating and dormant tumour cells as a function of time for the hyperfractionated (1.2 
Gy twice daily, 5 days per week to the dose of 72 Gy, “HF-72”) and accelerated hyperfractionated (1.6 
Gy twice daily, 5 days per week to the dose of 48 Gy, “AHF-48”) radiotherapy schedules. HF-72 is 
completed on day 40 after initiation of treatment whereas AHF-48 is completed on day 19.  (b) Total 
number of proliferating and dormant tumour cells as a function of time for the hyperfractionated (1.2 
Gy twice daily, 5 days per week to the dose of 64.8 Gy, “HF-64.8”) and accelerated hyperfractionated 
(1.6 Gy twice daily, 5 days per week to the dose of 48 Gy, “AHF-48”) radiotherapy schedules. HF-64.8 
is completed on day 37 after initiation of treatment whereas AHF-48 is completed on day 19. Both 
irradiation schedules start on the first day of the first week of treatment. (From Stamatakos G.S., V.P. 
Antipas, N.K. Uzunoglu, and R.G. Dale. 2006. A four dimensional computer simulation model of the in 
vivo response to radiotherapy of glioblastoma multiforme: studies on the effect of clonogenic cell 
density. Br J Radiol 79: 389-400. Reprinted with permission from the British Institute of Radiology, © 
2006 BIR) 
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